08.24.22
The Federal Trade Commission (FTC) is sending payments to 576 consumers nationwide who bought deceptively marketed cannabidiol (CBD) products from Arizona-based Kushly Industries LLC. In total, the FTC is returning almost $21,000 to consumers deceived by Kushly’s false or unsubstantiated claims about its CBD products, averaging $36 each.
The FTC’s March 2021 complaint against Kushly and the company’s CEO, Cody Alt, alleged that they made false or unsubstantiated claims that their CBD products could effectively treat or cure a host of conditions—from common ailments, like acne and psoriasis, to more serious diseases, including cancer and multiple sclerosis. The complaint also alleged that the company falsely claimed that scientific studies or research had proven CBD products effectively treat, mitigate, or cure diseases, including hypertension, Parkinson’s disease and Alzheimer’s disease.
The FTC’s March 2021 complaint against Kushly and the company’s CEO, Cody Alt, alleged that they made false or unsubstantiated claims that their CBD products could effectively treat or cure a host of conditions—from common ailments, like acne and psoriasis, to more serious diseases, including cancer and multiple sclerosis. The complaint also alleged that the company falsely claimed that scientific studies or research had proven CBD products effectively treat, mitigate, or cure diseases, including hypertension, Parkinson’s disease and Alzheimer’s disease.